AVCN Stock Overview
A commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Avicanna Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.26 |
| 52 Week High | CA$0.60 |
| 52 Week Low | CA$0.20 |
| Beta | 1.43 |
| 11 Month Change | -8.77% |
| 3 Month Change | -29.73% |
| 1 Year Change | -29.73% |
| 33 Year Change | -62.86% |
| 5 Year Change | -83.54% |
| Change since IPO | -95.83% |
Recent News & Updates
Take Care Before Jumping Onto Avicanna Inc. (TSE:AVCN) Even Though It's 31% Cheaper
Nov 17
Why Investors Shouldn't Be Surprised By Avicanna Inc.'s (TSE:AVCN) 35% Share Price Surge
Aug 28Recent updates
Take Care Before Jumping Onto Avicanna Inc. (TSE:AVCN) Even Though It's 31% Cheaper
Nov 17Why Investors Shouldn't Be Surprised By Avicanna Inc.'s (TSE:AVCN) 35% Share Price Surge
Aug 28Market Participants Recognise Avicanna Inc.'s (TSE:AVCN) Revenues Pushing Shares 79% Higher
Jul 11It's Down 35% But Avicanna Inc. (TSE:AVCN) Could Be Riskier Than It Looks
May 24Shareholders Should Be Pleased With Avicanna Inc.'s (TSE:AVCN) Price
Apr 05Here's Why Avicanna (TSE:AVCN) Can Afford Some Debt
Apr 18Shareholder Returns
| AVCN | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 10.6% | -6.9% | 2.2% |
| 1Y | -29.7% | -22.8% | 23.4% |
Return vs Industry: AVCN underperformed the Canadian Pharmaceuticals industry which returned -23.2% over the past year.
Return vs Market: AVCN underperformed the Canadian Market which returned 23.4% over the past year.
Price Volatility
| AVCN volatility | |
|---|---|
| AVCN Average Weekly Movement | 15.3% |
| Pharmaceuticals Industry Average Movement | 12.0% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.7% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: AVCN's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: AVCN's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 87 | Aras Azadian | www.avicanna.com |
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome.
Avicanna Inc. Fundamentals Summary
| AVCN fundamental statistics | |
|---|---|
| Market cap | CA$28.49m |
| Earnings (TTM) | -CA$6.80m |
| Revenue (TTM) | CA$24.90m |
1.1x
P/S Ratio-4.2x
P/E RatioIs AVCN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVCN income statement (TTM) | |
|---|---|
| Revenue | CA$24.90m |
| Cost of Revenue | CA$13.73m |
| Gross Profit | CA$11.17m |
| Other Expenses | CA$17.97m |
| Earnings | -CA$6.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.062 |
| Gross Margin | 44.86% |
| Net Profit Margin | -27.32% |
| Debt/Equity Ratio | 0.9% |
How did AVCN perform over the long term?
See historical performance and comparison